Overview

Safety and Efficacy of Bevacizumab in Combination With NaviFUS System for the Treatment of Recurrent Glioblastoma Multiforme (rGBM)

Status:
NOT_YET_RECRUITING

Trial end date:
2027-03-31

Target enrollment:

Participant gender:

Summary

This will be a prospective, open-label, single-arm pilot study to investigate the safety and efficacy of Bevacizumab (BEV) in combination with microbubble (MB)-mediated FUS in patients with recurrent GBM. BEV represents the physician's best choice for the standard of care (SoC) in rGBM after previous treatment with surgery (if appropriate), standard radiotherapy with temozolomide chemotherapy, and with adjuvant temozolomide.

Phase:

PHASE1

Details

Lead Sponsor:

NaviFUS Corporation

Collaborator:

NaviFUS US LLC

Treatments:

Bevacizumab
contrast agent BR1